Skip to Main Content
Olaf Stuve, M.D.,  Ph.D.

Olaf Stuve, M.D., Ph.D.

Chief of Neurology, Dallas Veterans Affairs Medical Center

Professor

School
Medical School
Department
Neurology
Graduate Programs
Immunology
  • Biography

    Joined UT Southwestern: 2005

    Dr. Olaf Stuve is a Professor in the Department of Neurology at UT Southwestern Medical Center, Head of the MS/ Neuroimmunology section, and Chief of Neurology at the VA North Texas Health Care System/ Dallas VA Medical Center. At the Dallas VA Medical Center, he attends to US veterans with multiple sclerosis (MS) and other neurological disorders.

    Research: Dr. Stuve has been the Principal Investigator and site Principal Investigator for numerous clinical trials.  Dr. Stuve also runs a research laboratory at UT Southwestern, studying the differential molecular requirements for bone-marrow-derived leukocytes to cross the blood-brain barrier or other biological barriers that provide immune privilege for the central nervous system (CNS).  He is also exploring molecular and cellular differences between bone-marrow-derived myeloid cell subsets and CNS-intrinsic microglia, and the potential pathogenic role of innate immune cells in early and late MS.  Furthermore, Dr. Stuve's research interests include molecular and cellular markers of autoimmunity, and experimental therapies for autoimmune disorders and has numerous ongoing collaborations with national and international investigators.

    Dr. Stuve’s research has been supported by grants from the Department of Veterans Affairs (VA), the National Multiple Sclerosis Society (NMSS), the Deutsche Forschungsgemeinschaft (DFG), and Boehringer Ingelheim Fonds. He has published over 300 research articles, review articles, editorials, and book chapters, and has given over 200 invited presentations. Dr. Stuve has served on numerous editorial boards of medical and scientific journals and has been a member of the National Institutes of Health (NIH), NMSS, and VA study sections.  Dr. Stuve is a past associate editor of JAMA Neurology and a past steering committee member of the Immune Tolerance Network (ITN).

    Trainee Education: Dr. Stuve has received numerous clinical teaching awards. Dr. Stuve has mentored undergraduate students, graduate students, medical students, residents, post-doctoral fellows, and faculty.  

    Awards: He is an elected member of the Alpha Omega Alpha (AOA) Honor Medical Society, and he is a recipient of a Clinical Scientist Development Award from the Doris Duke Charitable Foundation and a Grant for Multiple Sclerosis Innovation (GMSI) from Merck KGaA.   Dr. Stuve was elected Top Provider in Neurology at the VA North Texas Health Care System repeatedly by physician peers across medical and surgical specialties, and he has been listed in D Magazine's Best Doctors list.

    Background: Dr. Stuve received his medical degree from the Free University of Berlin, completed a medical doctoral thesis in physiology at the Max Delbruck Center for Molecular Medicine in Berlin magna cum laude, and earned a Ph.D. in immunology in the Department of Clinical and Experimental Immunology at Maastricht University.  He completed a transitional internship at the University of Cape Town, and a preliminary internship and neurology residency at the University of Washington in Seattle.  Dr. Stuve also received postdoctoral fellowship training in neuroimmunology at McGill University in Montreal, and the University of California, San Francisco (UCSF).

  • Education
    Medical School
    Freie University Berlin (1993), Medicine
    Medical School
    Max Delbruck Center for Molecu (1994), Physiology
    Graduate School
    Maastricht University (1994), Immunology
  • Research Interest
    • Experimental therapies for autoimmune disorders
    • Immune tolerance
    • Molecular and cellular markers of autoimmunity
  • Publications
    Multiple sclerosis treatments a review of current biomedical engineering approaches
    Mohseni SO, Au KM, Issa W, Ruan L, Stuve O, Wang AZ Biomaterials 2025 Feb 313
    Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials
    Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BA, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D The Lancet Neurology 2024 Nov 23 1119-1132
    Dimethyl fumarate preserves brainstem and cervical spinal cord integrity in radiologically isolated syndrome
    Author Collaboration ob, Okuda DT, Azevedo CJ, Pelletier D, Moog TM, Moazami S, Rezvani S, Bovis F, Sormani MP, Siva A, Kantarci O, Lebrun-Frénay C, Vargas WS, Stüve O, Repovic P, Pardo G, Okuda DT, Okai A, Naismith RT, Mowry EM, Hua LH, Donlon S, Azevedo CJ, Amezcua L Journal of neurology 2024 Sep 271 5899-5910
    A TH17-intrinsic IL-1β–STAT5 axis drives steroid resistance in autoimmune neuroinflammation
    Miller-Little WA, Chen X, Salazar V, Liu C, Bulek K, Zhou JY, Li X, Stüve O, Stappenbeck T, Dubyak G, Zhao J, Li X Science Immunology 2024 May 9
    Role of B Cells in Relapsing-Remitting and Progressive Multiple Sclerosis and Long-Term Effects of B Cell Depletion
    Shirani A, Stuve O, Cross AH Neurologic Clinics 2024 Feb 42 137-153
    Cladribine tablets after treatment with natalizumab (CLADRINA) – rationale and design
    Sguigna PV, Hussain RZ, Okai A, Blackburn KM, Tardo L, Madinawala M, Korich J, Lebson LA, Kaplan J, Salter A, Manouchehri N, Stuve O Therapeutic Advances in Neurological Disorders 2024 Jan 17
    Author response to Comment on: Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database
    Shirani A, Cross AH, Stuve O Therapeutic Advances in Neurological Disorders 2024 Jan 17
    A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis
    Airas L, Bermel RA, Chitnis T, Hartung HP, Nakahara J, Stuve O, Williams MJ, Kieseier BC, Wiendl H Therapeutic Advances in Neurological Disorders 2024 Jan 17
    Exploring the association of disease-modifying therapies for multiple sclerosis and BTK inhibitors with epilepsy
    Shirani A, Saez-Calveras N, Antel JP, Yaqubi M, Moore W, Brewster AL, Stuve O Therapeutic Advances in Neurological Disorders 2024 Jan 17
    Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database
    Shirani A, Cross AH, Stuve O Therapeutic Advances in Neurological Disorders 2024 Jan 17
  • Honors & Awards
    • D Magazine's Best Doctors list
      Neurology (2019)
    • D Magazine's Best Doctors list
      Neurology (2018)
    • Visiting Professorship
      University Erlangen, Germany (2017)
    • Alpha Omega Alpha (ΑΩΑ) Honor Medical Society
      Honorary member, Texas Gamma Chapter (2013)
    • Clinical Teaching Award Neurology
      University of Texas Southwestern Medical School, Class of 2012 (2011)
    • Clinical Teaching Award Neurology
      University of Texas Southwestern Medical School, Class of 2011 (2010)
    • Clinical Scientist Development Award
      Doris Duke Charitable Foundation (2009)
    • Clinical Teaching Award Neurology
      University of Texas Southwestern Medical School, Class of 2008 (2007)
    • Postdoctoral scholarship
      Boehringer Ingelheim Fonds (2001)
    • Advanced postdoctoral fellowship grant
      National Multiple Sclerosis Society (NMSS) (2000)
    • H.-L. Teuber price
      The Montreal Neurological Institute, McGill University, Montreal (1996)
    • Postdoctoral fellowship grant
      Deutsche Forschungsgemeinschaft (DFG), Germany (1995)
    • Magna cum laude M.D. thesis
      Free University of Berlin, Germany (1994)
  • Professional Associations/Affiliations
    • Department of Neurology, UT Southwestern (2005)
    • Neurology Section, VA North Texas Health Care System (2005)